Meiact (Cefditoren Pivoxil)

Cefditoren pivoxil is converted in the body to cefditoren, which binds to penicillin‑binding proteins on bacterial cell walls, blocking the synthesis of peptidoglycan. This weakens the wall, leading to osmotic rupture and bacterial death.

The dosage of Meiact is determined by the prescribing clinician based on the infection type, severity, patient age, weight, and renal function. Patients should follow the exact regimen provided by their healthcare professional.

The safety of cefditoren pivoxil in pregnancy and lactation has not been fully established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under medical supervision.

To request Meiact, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Cefditoren pivoxil offers a broad spectrum of activity against both Gram‑positive and Gram‑negative bacteria and is available as an oral formulation, which can be more convenient than injectable third‑generation cephalosporins. Its pharmacokinetic profile allows once‑daily dosing for many indications, but choice of therapy should be guided by susceptibility data and clinical guidelines.

Store Meiact at room temperature, below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Meiact is taken orally, usually with a full glass of water. It can be taken with or without food, but consistent administration with respect to meals helps maintain stable absorption. Patients should swallow the tablet whole and not crush or chew it unless instructed otherwise.

Serious risks include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, Stevens‑Johnson syndrome, liver injury, neutropenia, and hemolytic anemia. Patients should seek immediate medical attention if they experience rash, fever, persistent diarrhea, jaundice, or signs of bleeding.

Meiact should be avoided in individuals with a known hypersensitivity to cefditoren, other cephalosporins, or penicillins. Caution is also advised for patients with severe renal or hepatic impairment, and it is contraindicated in those with a history of severe allergic reactions to β‑lactam antibiotics.